Table 4.
Sensitivity analysis
| HR | 95 % CI | p value | |
|---|---|---|---|
| Landmark analysis | |||
| APM use | |||
| Unexposed | 1.00 | ||
| Exposed (0–9 months) | 1.23 | 0.70–2.51 | 0.48 |
| Exposed (9+ months) | 0.79 | 0.55–1.13 | 0.20 |
| Age | |||
| 0–70 | 1.00 | ||
| 70+ | 1.39 | 1.23–1.58 | <0.0001 |
| Stage | |||
| I | 1.00 | ||
| II | 1.49 | 1.15–1.95 | 0.003 |
| III | 2.79 | 2.34–3.33 | <0.0001 |
| IV | 4.83 | 4.03–5.79 | <0.0001 |
| Unknown/missing | 1.60 | 1.15–2.22 | 0.01 |
| Histology | |||
| Non-adeno | 1.00 | ||
| Adeno | 0.77 | 0.67–0.0.89 | 0.0004 |
| SCLC | 1.26 | 1.02–1.54 | 0.03 |
| History of prostate ca | |||
| No | 1.00 | ||
| Yes | 1.03 | 0.80–1.33 | 0.79 |
| Immediate time-varying model | |||
| APM use | |||
| Non-user | 1.00 | ||
| Current | 0.85 | 0.69–1.05 | 0.13 |
| Former | 0.65 | 0.32–1.30 | 0.22 |
| Age (10-year increments) | 1.23 | 1.19–1.28 | <0.0001 |
| Stage | |||
| I | 1.00 | ||
| II | 1.50 | 1.15–1.95 | 0.001 |
| III | 3.28 | 2.34–3.33 | <0.0001 |
| IV | 6.66 | 4.03–5.79 | <0.0001 |
| Unknown/missing | 3.07 | 1.15–2.22 | <0.0001 |
| Histology | |||
| Non-adeno | 1.00 | ||
| Adeno | 0.82 | 0.74–0.0.90 | <0.0001 |
| SCLC | 1.02 | 0.82–1.16 | 0.82 |